JP2015514716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514716A5 JP2015514716A5 JP2015503652A JP2015503652A JP2015514716A5 JP 2015514716 A5 JP2015514716 A5 JP 2015514716A5 JP 2015503652 A JP2015503652 A JP 2015503652A JP 2015503652 A JP2015503652 A JP 2015503652A JP 2015514716 A5 JP2015514716 A5 JP 2015514716A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- fragment
- sample
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 98
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 98
- 239000000523 sample Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 51
- 238000010186 staining Methods 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 229940127121 immunoconjugate Drugs 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 31
- 238000001514 detection method Methods 0.000 claims description 31
- 239000012472 biological sample Substances 0.000 claims description 14
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 239000002619 cytotoxin Substances 0.000 claims description 10
- 101710112752 Cytotoxin Proteins 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002055 immunohistochemical effect Effects 0.000 claims description 6
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 6
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 6
- 229960005558 mertansine Drugs 0.000 claims description 6
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical group C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 4
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 4
- -1 taxoid Chemical compound 0.000 claims description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052722 tritium Inorganic materials 0.000 claims description 3
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 claims description 2
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- ORKSBKSSOSUJOY-UHFFFAOYSA-N 2,5-dioxo-1-[4-(pyridin-2-yldisulfanyl)pentanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O ORKSBKSSOSUJOY-UHFFFAOYSA-N 0.000 claims description 2
- OWDQCSBZQVISPN-UHFFFAOYSA-N 2-[(2,5-dioxopyrrolidin-1-yl)amino]-4-(2-iodoacetyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-N 0.000 claims description 2
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims description 2
- JNWSNQJRTXEHIV-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfopentanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CC(C)SSC1=CC=CC=N1 JNWSNQJRTXEHIV-UHFFFAOYSA-N 0.000 claims description 2
- 240000006409 Acacia auriculiformis Species 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims description 2
- 201000000638 mature B-cell neoplasm Diseases 0.000 claims description 2
- 208000010915 neoplasm of mature B-cells Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 26
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 238000004043 dyeing Methods 0.000 claims 3
- 101150066967 CD37 gene Proteins 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 238000003364 immunohistochemistry Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000920340 Pion Species 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618489P | 2012-03-30 | 2012-03-30 | |
| US61/618,489 | 2012-03-30 | ||
| PCT/US2013/034646 WO2013149171A2 (en) | 2012-03-30 | 2013-03-29 | Methods for increasing efficacy of cd37-based therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514716A JP2015514716A (ja) | 2015-05-21 |
| JP2015514716A5 true JP2015514716A5 (OSRAM) | 2016-04-28 |
Family
ID=49261399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503652A Withdrawn JP2015514716A (ja) | 2012-03-30 | 2013-03-29 | Ｃｄ３７に基づく治療の有効性を増大させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150093397A1 (OSRAM) |
| EP (1) | EP2831585A4 (OSRAM) |
| JP (1) | JP2015514716A (OSRAM) |
| KR (1) | KR20140143810A (OSRAM) |
| CN (1) | CN104364651A (OSRAM) |
| AU (1) | AU2013237826A1 (OSRAM) |
| BR (1) | BR112014024487A2 (OSRAM) |
| CA (1) | CA2868049A1 (OSRAM) |
| HK (1) | HK1202156A1 (OSRAM) |
| IL (1) | IL234813A0 (OSRAM) |
| MX (1) | MX2014011745A (OSRAM) |
| RU (1) | RU2014140119A (OSRAM) |
| SG (1) | SG11201405766SA (OSRAM) |
| WO (1) | WO2013149171A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900549T1 (it) | 2010-03-12 | 2019-11-13 | Debiopharm Int Sa | Molecole leganti il cd37 e loro immunoconiugati |
| EA201391342A1 (ru) | 2011-04-01 | 2014-11-28 | Иммьюноджен, Инк. | Cd37-связывающие молекулы и их иммуноконъюгаты |
| WO2015175533A2 (en) * | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| MX392539B (es) * | 2015-06-08 | 2025-03-24 | Debiopharm Int Sa | Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20. |
| UA129489C2 (uk) | 2015-08-28 | 2025-05-14 | Дебіофарм Інтернаціонал, С.А. | Антитіло до cd37 |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| CN107603276A (zh) * | 2017-09-14 | 2018-01-19 | 郑州乐业生物科技有限公司 | 一种稳定的生物染色剂及其制备方法 |
| CN110511900B (zh) * | 2018-05-21 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 精子细胞表面标志物的筛选与应用 |
| CN112218662A (zh) | 2018-05-30 | 2021-01-12 | 德彪发姆国际有限公司 | 抗cd37免疫缀合物给药方案 |
| US20230184639A1 (en) * | 2020-05-29 | 2023-06-15 | Sony Group Corporation | Information processing device, information processing method, computer program, and target molecule detection system |
| CN111579798A (zh) * | 2020-05-29 | 2020-08-25 | 深圳市锦欣医疗科技创新中心有限公司 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
| RU2767693C1 (ru) * | 2021-03-03 | 2022-03-18 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ морфометрической оценки прогноза течения диффузной B-крупноклеточной лимфомы по индексу доли опухолевых клеток, экспрессирующих pSTAT3 и pAKT1 в лимфатических узлах |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318906B2 (en) * | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2009085576A2 (en) * | 2007-12-28 | 2009-07-09 | Spring Bioscience Corporation | Positive control cell pellets for immunohistochemistry and methods of use thereof |
| ES2368700T3 (es) * | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo. |
| RU2526156C2 (ru) * | 2008-11-13 | 2014-08-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Cd37-иммунотерапевтическая комбинированная терапия и ее применения |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| SMT201900549T1 (it) * | 2010-03-12 | 2019-11-13 | Debiopharm Int Sa | Molecole leganti il cd37 e loro immunoconiugati |
| EP2558501B1 (en) * | 2010-04-15 | 2016-09-07 | Alper Biotech, Llc | Monoclonal antibodies against her2 antigens, and uses therefor |
-
2013
- 2013-03-29 JP JP2015503652A patent/JP2015514716A/ja not_active Withdrawn
- 2013-03-29 CN CN201380018486.5A patent/CN104364651A/zh active Pending
- 2013-03-29 MX MX2014011745A patent/MX2014011745A/es unknown
- 2013-03-29 KR KR1020147030199A patent/KR20140143810A/ko not_active Withdrawn
- 2013-03-29 CA CA2868049A patent/CA2868049A1/en not_active Abandoned
- 2013-03-29 US US14/389,727 patent/US20150093397A1/en not_active Abandoned
- 2013-03-29 HK HK15102580.5A patent/HK1202156A1/xx unknown
- 2013-03-29 RU RU2014140119A patent/RU2014140119A/ru not_active Application Discontinuation
- 2013-03-29 EP EP13770074.6A patent/EP2831585A4/en not_active Withdrawn
- 2013-03-29 AU AU2013237826A patent/AU2013237826A1/en not_active Abandoned
- 2013-03-29 WO PCT/US2013/034646 patent/WO2013149171A2/en not_active Ceased
- 2013-03-29 BR BR112014024487A patent/BR112014024487A2/pt not_active IP Right Cessation
- 2013-03-29 SG SG11201405766SA patent/SG11201405766SA/en unknown
-
2014
- 2014-09-23 IL IL234813A patent/IL234813A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514716A5 (OSRAM) | ||
| Kinneer et al. | SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads | |
| JP2014513068A5 (OSRAM) | ||
| Hurley et al. | 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer | |
| Saadeh et al. | EGFR as a clinical marker in glioblastomas and other gliomas | |
| JP2024099612A (ja) | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 | |
| Lok et al. | PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer | |
| Li et al. | A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy | |
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| Hamblett et al. | AMG 595, an anti-EGFRvIII antibody–drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma | |
| Zhou et al. | Neddylation inhibition upregulates PD‐L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma | |
| Chapiro et al. | Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53 | |
| Salles et al. | Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma | |
| Kuo et al. | p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors | |
| Yaromina et al. | Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability | |
| Tarantelli et al. | Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy | |
| Kim et al. | Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation | |
| Zhang et al. | A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia | |
| Kim et al. | In vivo monitoring of CD44+ cancer stem-like cells by γ-irradiation in breast cancer | |
| Wilkinson et al. | Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation | |
| US20180105882A1 (en) | New biomarker for outcome in aml | |
| Ennishi et al. | Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy | |
| Yang et al. | Immunohistochemical detection of poly (ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas | |
| Takata et al. | Identification of TRA‐1‐60‐positive cells as a potent refractory population in follicular lymphomas | |
| Bouley et al. | Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss |